文献速递心律失常冠心病

房颤合并稳定性冠心病支架术后1年以上:单用口服抗凝与联合单抗血小板治疗的开放标签随机试验

Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation.
PubMed 文献 · Circulation · 2019-01-01

本研究为前瞻性、多中心、开放标签、非劣效性随机试验,纳入房颤且冠脉支架术后超过1年的患者,比较单用口服抗凝(OAC)与OAC联合单抗血小板治疗(APT)。原计划入组2000例,实际提前终止于696例。中位随访2.5年,主要终点单用OAC组15.7% vs 联合组13.6%(HR 1.16,95%CI 0.79-1.72),非劣效性未成立;因样本量不足,研究效能不足且结论不确定。

要点

  • 房颤合并稳定性冠心病支架术后1年以上,单用OAC未证实非劣效于OAC联合单APT。
  • 主要终点单用OAC组15.7% vs 联合组13.6%,HR 1.16(95%CI 0.79-1.72)。
  • 研究提前终止、样本量不足,结果不确定,需更大规模研究确定最佳抗栓方案。

核心结论

  • 本随机试验未确立单用OAC对OAC联合单APT在房颤合并稳定性冠心病支架术后1年以上患者中的非劣效性。
  • 因入组提前终止,研究效能不足且结论不确定,需未来更大规模研究确定该人群最佳抗栓方案。

研究设计与样本

  • 前瞻性、多中心、开放标签、非劣效性随机对照试验,按1:1随机分为单用OAC组与OAC联合单APT组。
  • 计划12个月入组2000例,实际38个月入组696例后提前终止;中位随访2.5年。
  • 纳入房颤且冠脉支架术后超过1年的患者;平均年龄75.0±7.6岁,男性85.2%,平均CHADS2评分2.5±1.2。
  • OAC为华法林者75.2%,直接口服抗凝药者24.8%。

主要发现

  • 主要终点(全因死亡、心肌梗死、卒中或系统性栓塞)单用OAC组54例(15.7%),联合组47例(13.6%);HR 1.16(95%CI 0.79-1.72),非劣效性P=0.20,优效性P=0.45。
  • 主要次要终点(主要终点或ISTH定义的大出血)单用OAC组67例(19.5%),联合组67例(19.4%);HR 0.99(95%CI 0.71-1.39),非劣效性P=0.016,优效性P=0.96。
  • 心肌梗死单用OAC组8例(2.3%),联合组4例(1.2%);卒中或系统性栓塞分别为13例(3.8%)与19例(5.5%)。
  • 大出血单用OAC组27例(7.8%),联合组36例(10.4%)。

临床怎么用

  • 对于房颤合并稳定性冠心病支架术后超过1年的患者,本研究因效能不足无法支持单用OAC替代OAC联合单APT。
  • 临床决策仍需依据现有指南推荐,并个体化评估缺血与出血风险。

局限性

  • 入组提前终止,实际样本量696例远低于计划的2000例,研究效能不足。
  • 开放标签设计可能引入偏倚。
  • 研究结论不确定,无法确立单用OAC的非劣效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite recommendations in the guidelines and consensus documents, there has been no randomized controlled trial evaluating oral anticoagulation (OAC) alone without antiplatelet therapy (APT) in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after coronary stenting. METHODS: This study was a prospective, multicenter, open-label, noninferiority trial comparing OAC alone to combined OAC and single APT among patients with atrial fibrillation beyond 1 year after stenting in a 1:1 randomization fashion. The primary end point was a composite of all-cause death, myocardial infarction, stroke, or systemic embolism. The major secondary end point was a composite of the primary end point or major bleeding according to the International Society on Thrombosis and Haemostasis classification. Although the trial was designed to enroll 2000 patients during 12 months, enrollment was prematurely terminated after enrolling 696 patients in 38 months. RESULTS: Mean age was 75.0±7.6 years, and 85.2% of patients were men. OAC was warfarin in 75.2% and direct oral anticoagulants in 24.8% of patients. The mean CHADS2 score was 2.5±1.2. During a median follow-up interval of 2.5 years, the primary end point occurred in 54 patients (15.7%) in the OAC-alone group and in 47 patients (13.6%) in the combined OAC and APT group (hazard ratio, 1.16; 95% CI, 0.79-1.72; P=0.20 for noninferiority, P=0.45 for superiority). The major secondary end point occurred in 67 patients (19.5%) in the OAC-alone group and in 67 patients (19.4%) in the combined OAC and APT group (hazard ratio, 0.99; 95% CI, 0.71-1.39; P=0.016 for noninferiority, P=0.96 for superiority). Myocardial infarction occurred in 8 (2.3%) and 4 (1.2%) patients, whereas stroke or systemic embolism occurred in 13 (3.8%) and 19 (5.5%) patients, respectively. Major bleeding occurred in 27 (7.8%) and 36 (10.4%) patients, respectively. CONCLUSIONS: This randomized trial did not establish noninferiority of OAC alone to combined OAC and APT in patients with atrial fibrillation and stable coronary artery disease beyond 1 year after stenting. Because patient enrollment was prematurely terminated, the study was underpowered and inconclusive. Future larger studies are required to establish the optimal antithrombotic regimen in this population. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT01962545.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Matsumura-Nakano Y, Shizuta S, Komasa A, et al. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation. Circulation. 2019. PMID: 30586700. doi:10.1161/CIRCULATIONAHA.118.036768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。